A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.
about
Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacyThe potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysisBack to thiazide-diuretics for hypertension: reflections after a decade of irrational prescribingDiabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trialsTimeline of History of Hypertension TreatmentWhat is an appropriate blood pressure goal for the elderly: review of recent studies and practical recommendationsManaging hypertension in the elderly: a common chronic disease with increasing ageAngiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patientsRole of estrogen in diastolic dysfunctionPrimary prevention of coronary heart disease in the elderlyQueen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the hypertension clinic 1996-2004Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseasesEffects of treatment with zofenopril in men and women with acute myocardial infarction: gender analysis of the SMILE ProgramNovel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.Why not prescribe the best drugs for hypertension now?The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease.RAAS inhibitors and cardiovascular protection in large scale trials.A pragmatic cluster randomised controlled trial to evaluate the safety, clinical effectiveness, cost effectiveness and satisfaction with point of care testing in a general practice setting - rationale, design and baseline characteristicsNoninvasive measurement of central vascular pressures with arterial tonometry: clinical revival of the pulse pressure waveform?Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis.The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registry.Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research.Morbidity and mortality of orthostatic hypotension: implications for management of cardiovascular disease.Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall.Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review.Do advertisements for antihypertensive drugs in Australia promote quality prescribing? A cross-sectional study.Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analysesPredicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST.Blood pressure and ageing.Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004.Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertensionRisk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trialsThiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension.Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.Performance of the modified Poisson regression approach for estimating relative risks from clustered prospective data.Risk of thiazide-induced metabolic adverse events in older adults.Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007-2010.The past, present and future of renin-angiotensin aldosterone system inhibitionSerum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study.
P2860
Q24652838-893F7574-CFE7-40D7-AD17-91A3A4823E51Q24801524-5FA8596C-F9DF-48C2-846C-3EF7F85FAB2EQ24805075-05DA7BA3-D4BC-447D-9B24-5F27044667CEQ26766599-642D7F26-A217-497E-801C-E4BCC0C6E5A4Q26768219-08C1C07F-E867-482E-9639-1CDE3C07D0F6Q26864349-B89FD622-5CCC-47BA-B25C-2963B9EED8CCQ27011805-7168C560-B25C-4855-84BF-4B0954ED2B9CQ27023161-80519B07-8807-4F72-B412-A0265552B1A4Q27026798-59C5D546-29A9-4124-81DA-3E435C86E37DQ28165739-785BF51E-7EEC-40B2-B95F-8C204F45842FQ28180976-25E9B894-7206-47CD-BD9B-8F5B94D7CAF3Q28182631-C99B8145-F96C-4253-849B-37D96BD5A510Q28544671-6B83C1C1-C859-4F54-AF6A-0339660855B5Q30235583-376EDD37-1851-4018-9F1C-D071946E1A6CQ30333019-0861BD61-CB7A-41CB-B19F-618CBBFDD91BQ30340930-2DC5D7F4-6B56-4F93-B06F-7D4A4FED822BQ30424541-FB4435E0-4E06-4949-BA37-30F2EE762AFBQ30483158-1A790C36-A336-4D4D-8B86-96BDCDCF00FEQ30494287-B8BF623F-D6C1-42E3-92AC-87F98D5A88F5Q30514101-B42D6D60-7029-403F-9A26-FED7FAEEBF9AQ30615846-F06AEAB9-8282-4466-8B8C-2A44FC9C309FQ30883430-30E0EA56-7402-4BF1-8249-43F4FD4FC9A3Q33159154-958D2BB8-51B4-410D-A189-5CD0DF6A7F7CQ33239013-50A38A02-1763-46EF-AA66-A4CE06ACE766Q33300205-2606B4BF-EAC3-414B-A943-ECCD95C3A05EQ33336223-395C8748-9494-454B-9F76-A0CDE165ACEDQ33561456-AA1F5D92-E9B1-4FF4-9DED-96F86C606454Q33576830-41B27921-75F8-46E5-BB7D-0614F5097EF6Q33585444-EF944573-F3AD-409B-8561-B2F5A4ED169BQ33588483-2B5799B4-A77A-4A41-862F-1A3046D42331Q33638261-1405625C-0F97-46D5-83C3-210DA500A090Q33710477-BEB9272E-25C7-4F36-8DC6-B4DF3BE8B137Q33768602-8E787BAD-AD16-4CFD-A552-F51CA1145114Q33964868-00E0B0EA-A625-4023-8F32-32E7A35387A3Q33965660-DF234193-054B-4EC4-9FB7-182C6FD39C17Q33992849-0B110A88-E690-44AB-9253-103EC886A5A0Q34026623-A3136F85-E90E-40EF-B70F-A9825A8342D9Q34084060-E8BD69A2-D1FA-4F9A-B397-0766F214FAA7Q34094354-6364C02A-C3F9-4679-B8BA-CC02C386E4ABQ34125686-00216D80-497A-4DFE-9FC1-4D2389FECBE5
P2860
A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A comparison of outcomes with ...... r hypertension in the elderly.
@ast
A comparison of outcomes with ...... r hypertension in the elderly.
@en
A comparison of outcomes with ...... r hypertension in the elderly.
@nl
type
label
A comparison of outcomes with ...... r hypertension in the elderly.
@ast
A comparison of outcomes with ...... r hypertension in the elderly.
@en
A comparison of outcomes with ...... r hypertension in the elderly.
@nl
prefLabel
A comparison of outcomes with ...... r hypertension in the elderly.
@ast
A comparison of outcomes with ...... r hypertension in the elderly.
@en
A comparison of outcomes with ...... r hypertension in the elderly.
@nl
P2093
P356
P1476
A comparison of outcomes with ...... or hypertension in the elderly
@en
P2093
Christopher M Reid
Colin I Johnston
Graham J Macdonald
John E Marley
John J McNeil
Lawrence J Beilin
Lindon M H Wing
Malcolm J West
Mark A Brown
Philip Ryan
P304
P356
10.1056/NEJMOA021716
P407
P577
2003-02-01T00:00:00Z